摘要
目的探讨利拉鲁肽联合盐酸二甲双胍治疗维吾尔族和汉族肥胖2型糖尿病(T2DM)的临床疗效。方法采用开放式随机对照研究的方法,按照序贯进入的原则,选择新疆医科大学第一附属医院住院的肥胖T2DM患者132例,其中利拉鲁肽+盐酸二甲双胍组66例(维吾尔族21例,汉族45例),盐酸二甲双胍组66例(维吾尔族29例,汉族37例)。比较两组患者治疗前及治疗后3、6个月体质指数(BMI)、糖化血红蛋白(HBA1c)、腰臀比(WHR)、空腹血糖、餐后2 h血糖、收缩压/舒张压及低密度脂蛋白的变化情况,并比较不同民族间各项指标的变化情况。结果利拉鲁肽+盐酸二甲双胍组肥胖T2DM患者治疗后3、6个月时的BMI、HBA1c、WHR、空腹血糖及餐后2 h血糖较治疗前均下降,且下降的幅度高于盐酸二甲双胍组,差异具有统计学意义(P<0.05);利拉鲁肽+二甲双胍组肥胖T2DM患者治疗后3、6个月时的收缩压/舒张压、低密度脂蛋白较治疗前均有所下降,但下降幅度偏小,两组比较差异无统计学意义(P>0.05)。利拉鲁肽+盐酸二甲双胍组维吾尔族患者治疗后3、6个月时的BMI、HBA1c、WHR、空腹血糖及餐后2 h血糖较治疗前均下降,且下降的幅度大于汉族患者,差异具有统计学意义(P<0.05)。结论利拉鲁肽联合盐酸二甲双胍在降低肥胖T2DM患者的BMI、HBA1c、WHR、空腹血糖及餐后2 h血糖要优于单用二甲双胍,可作为肥胖T2DM患者的优选治疗方案;利拉鲁肽联合二甲双胍治疗方案对维吾尔族肥胖T2DM患者效果明显,可作为其降糖的优先治疗方案。
Objective Observation of clinical effects of liraglutide combined with mefformin on type 2 diabetes mellitus with obesity. Methods The randomized and controlled open-label trial involved 132 patients with obesity and type 2 diabetes,who were randomly assigned to groups of receiving Liraglutide combined with mefformin（ n =66,uygur = 21,han = 45） or mefformin alone（ n = 66,uygur = 29,han = 37） for 24 weeks. The changes of BMI,HBA1 c,waist-hip ratio,fasting glucose treatment,postprandial blood sugar 2 hours,systolic / diastolic blood pressure and low density lipoprotein cholesterol before the treatment and after treatment of 3 months or 6 months were compared. And,the indexes above of different nationalities were compared too. Results After treatment for 3months or 6 months,BMI,HBA1 c,waist-hip ratio,fasting glucose treatment and postprandial blood sugar 2 hours of the experimental group were decreased than that of the control group（ P〈0. 05）. The systolic / diastolic blood pressure and low density lipoprotein cholesterol（ hdl-c） of experimental group were declined,but the small decline compared with that of the control group and no statistical difference（ P〉0. 05）. After treatment,the BMI,HBA1 c,waist-hip ratio,fasting glucose treatment,postprandial blood sugar 2 hours of Uygur was improved greater than that of the Han（ P〈0. 05）. Conclusion The effects of Liraglutide combined with mefformin is superior to metformin only,and could be used as optimization of obese patients with T2 DM treatment,and especially for the Uygur.
出处
《新疆医科大学学报》
CAS
2015年第12期1527-1530,1535,共5页
Journal of Xinjiang Medical University
基金
新疆维吾尔自治区自然科学基金(2013211A093)
作者简介
姚亚妮（1982-），女，硕士，主治医师，研究方向：肥胖2型糖尿病及运动障碍性疾病。
通信作者：王玉玲，女，在读博士，主任医师，研究方向：肥胖2型糖尿病，Email：clwyl@yeah．net。
